Laura Sepp-Lorenzino
Chief Tech/Sci/R&D Officer bei INTELLIA THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Dr. Laura Sepp-Lorenzino ist ein unabhängiges Vorstandsmitglied bei Taysha Gene Therapies, Inc. und Chief Scientific Officer & Executive VP bei Intellia Therapeutics, Inc. Sie ist Mitglied des Board of Directors bei Taysha Gene Therapies, Inc. Dr. Sepp-Lorenzino war zuvor als VP, Head-Nucleic Acid Therapies & Research bei Vertex Pharmaceuticals, Inc. beschäftigt, als Vice President bei Alnylam Pharmaceuticals, Inc. und als Executive Director & Head-RNA Therapeutics bei Merck & Co, Inc. Sie erhielt ihren Bachelor-Abschluss von der Universidad de Buenos Aires, einen Graduierten-Abschluss von der New York University und einen Doktortitel von der New York University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
01.03.2024 | 81 893 ( 0,09% ) | 2 Mio $ | 31.03.2024 | |
18.09.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Laura Sepp-Lorenzino
Unternehmen | Position | Beginn |
---|---|---|
INTELLIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 28.05.2019 |
TAYSHA GENE THERAPIES, INC. | Director/Board Member | 23.11.2020 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | - |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | - |
Ehemalige bekannte Positionen von Laura Sepp-Lorenzino
Unternehmen | Position | Ende |
---|---|---|
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.05.2019 |
ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.09.2017 |
MERCK & CO., INC. | Director/Board Member | 01.03.2014 |
Ausbildung von Laura Sepp-Lorenzino
New York University | Doctorate Degree |
Universidad de Buenos Aires | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
MERCK & CO., INC. | Health Technology |
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
INTELLIA THERAPEUTICS, INC. | Health Technology |
TAYSHA GENE THERAPIES, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |